Fujifilm Holdings Corporation (TSE: 4901) is a Japanese multinational conglomerate headquartered in Tokyo, Japan, with significant operations in healthcare and pharmaceuticals. The company's pharmaceutical division, Fujifilm Toyama Chemical Co., Ltd., has been developing novel therapeutics for central nervous system disorders, including the sigma-1 receptor agonist T-817MA for Alzheimer's and Parkinson's disease[1].
Fujifilm has leveraged its expertise in chemical synthesis and drug development to advance a pipeline of CNS-targeting compounds, with T-817MA representing their lead program in the neurodegeneration space.
T-817MA is a selective sigma-1 receptor agonist developed by Fujifilm Toyama Chemical for the treatment of neurodegenerative diseases:
| Attribute | Value |
|---|---|
| Target | Sigma-1 receptor (SIGMAR1) |
| Mechanism | Sigma-1 receptor agonist, neuroprotection |
| Indication | Alzheimer's disease, Parkinson's disease |
| Development Stage | Phase II (Japan) |
| Route | Oral |
T-817MA exerts neuroprotective effects through sigma-1 receptor activation:
Studies in preclinical models have demonstrated[2]:
| Trial | Phase | Indication | Status | Notes |
|---|---|---|---|---|
| NCT02052271 | Phase I | Alzheimer's disease | Completed | Safety and tolerability established |
| NCT02873390 | Phase II | Alzheimer's disease | Completed | Japan |
| TBD | Phase II | Parkinson's disease | Planning | Based on preclinical PD data |
T-817MA represents Fujifilm's entry into the sigma-1 receptor agonist field:
| Factor | T-817MA | Blarcamesine (Anavex) | Notes |
|---|---|---|---|
| Selectivity | High sigma-1 | Sigma-1 + muscarinic | Different mechanism |
| Development stage | Phase II (Japan) | Phase II/III (global) | Blarcamesine ahead |
| Geography | Japan-focused | Global | Different markets |
| Formulation | Oral | Oral | Similar delivery |
| Program | Target | Indication | Stage |
|---|---|---|---|
| T-817MA | Sigma-1R | Alzheimer's/Parkinson's | Phase II |
| T-2558 | Undisclosed | CNS | Preclinical |
| T-3889 | Undisclosed | Rare disease | Research |
Headquarters: Tokyo, Japan
Founded: 1934 (as Fujifilm Corporation)
Ticker: TSE 4901
Healthcare Division: Fujifilm Toyama Chemical Co., Ltd.
Key Focus Areas:
Fujifilm's entry into sigma-1 receptor agonists reflects their broader strategy to expand in CNS therapeutics:
T-817MA Sigma-1 agonist preclinical data. J Pharmacol Sci. 2020. ↩︎